Your session is about to expire
← Back to Search
Alkylating agent
Oxaliplatin + Paclitaxel for Solid Tumors
Phase 1
Waitlist Available
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Renal: Creatinine normal OR Creatinine clearance at least 60 mL/min
Hepatic: Bilirubin normal, SGOT/SGPT no greater than 2.5 times upper limit of normal
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is testing the combination of two drugs, oxaliplatin and paclitaxel, to see if it is more effective in treating metastatic or unresectable cancer than either drug alone.
Who is the study for?
This trial is for adults with advanced cancers that can't be removed by surgery or have spread, and standard treatments aren't working. They must not have brain metastases, serious heart conditions, severe infections, or certain blood disorders. Pregnant women and those not using contraception are excluded.Check my eligibility
What is being tested?
The study is testing the combination of two chemotherapy drugs, oxaliplatin and paclitaxel, to see how effective they are in treating patients with metastatic or unresectable cancer. It's a Phase I trial which usually means it's early in testing and looking at safe dosage levels.See study design
What are the potential side effects?
Oxaliplatin may cause nerve damage leading to numbness or tingling sensations. Paclitaxel can result in hair loss, joint pain, muscle pains and an increased risk of infection due to low white blood cell counts.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My kidney function is normal or nearly normal.
Select...
My liver function tests are within normal limits.
Select...
My cancer is advanced and standard treatments are not effective or available.
Select...
I am 18 years old or older.
Select...
I do not have heart failure, unstable chest pain, or irregular heartbeats.
Select...
I do not have cancer that has spread to my brain.
Select...
I can take care of myself but might not be able to do heavy physical work.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
Ohio State University Comprehensive Cancer CenterLead Sponsor
316 Previous Clinical Trials
289,686 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,609 Previous Clinical Trials
40,915,646 Total Patients Enrolled
Eric H. Kraut, MDStudy ChairOhio State University Comprehensive Cancer Center
3 Previous Clinical Trials
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My kidney function is normal or nearly normal.I am not pregnant, not nursing, use birth control, have no severe allergies, and no serious illnesses or infections.My liver function tests are within normal limits.My cancer is advanced and standard treatments are not effective or available.I am not on any experimental drugs or HIV treatments.I am 18 years old or older.I do not have heart failure, unstable chest pain, or irregular heartbeats.I've had no more than 2 chemotherapy treatments, none with oxaliplatin or paclitaxel, and it's been 4 weeks since my last treatment.It's been over 4 weeks since my last radiotherapy, and I haven't had radiotherapy to more than 25% of my bone marrow.I do not have cancer that has spread to my brain.I can take care of myself but might not be able to do heavy physical work.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any openings remaining for participants in this clinical trial?
"According to clinicaltrials.gov, this trial is not currently seeking participants as the data was last updated on May 14th 2013. Nonetheless, there are 41 other studies actively recruiting patients at this time despite the lack of availability for this particular medical study which debuted on October 1st 1999."
Answered by AI
Has this treatment been approved by the Federal Drug Administration?
"At this time, the safety of this treatment has only been evaluated in a Phase 1 trial and thus is estimated at level 1 given the limited data available."
Answered by AI
Recent research and studies
Share this study with friends
Copy Link
Messenger